This link will take you to a page that’s not on LinkedIn

I just read a post Tiny Stories: Why I Write by my friend, Marie Ennis-O'Connor  She wrote her piece because of a prompt suggested by Linda...

Gynecologic malignancies accounted for ∼15 % of new cancer cases and cancer survivors in 2022. Advances in cancer care are expected to improve outcomes, and the growth in survivorship is expected to i...

Participate in a groundbreaking study to advance breast cancer treatment. Receive a genetic ancestry report. Open to US residents 18+.

I haven't written a blog post in quite some time. It seems that life got in the way of my writing. Then, once I had time,  I couldn't seem t...

Recurrent ovarian cancer (OC) is challenging to detect early using current methods like CA-125 and imaging. Circulating tumor DNA (ctDNA) may improve disease monitoring. Here, we assess the real-world clinical utility of serial ctDNA analyses in patients with recurrent OC. We analyzed serial plasma …

YouTube video by Outperform Cancer with Marybeth Gilliam

I spoke about how there are symptoms of ovarian cancer( gloating, freq urination etc) in my previous post. What happens when you go to your ...

I follow the Foundation for Women's Cancer and loved the design of this graphic for #GCAM. I would change the hashtag #ASKHER to #ASKME.    ...

I am not sure where the month of August went and here we are starting September. If you have followed me for any period of time you are prob...

AbstractPurpose:. Minimal residual disease (MRD) after first-line treatment of advanced-stage ovarian cancer remains a long-standing barrier to cure. We investigated the prognostic and translational v...

Consensus document from four international groups

Consensus document from four international groups

Advances in biological and molecular understanding of these diseases have made a difference

After 3 years of follow-up, dostarlimab plus chemotherapy was effective and tolerable in patients aged 70 years or older with endometrial cancer.

Empowering Oncologists: Who speaks up for patients far from the center? / cancer, Dr. Jasmine Kamboj, Dr. Wade Swenson, Empowering Oncologists, OncoDaily,

The TRUST trial is the first phase III randomized study to show improved progression-free survival for primary cytoreductive surgery compared with interval surgery without compromising short-term or l...

It has been a busy June for me with family and personal commitments. I was able to attend the ASCO annual meeting virtually and have picked ...

From 2014 through 2019, the US Food and Drug Administration (FDA) granted approval to six indications for poly (ADP-ribose) polymerase (PARP) inhibitors in advanced epithelial ovarian cancer (EOC). Fr...

The NIH has scaled back its awards of new grants by at least $2.3 billion since the beginning of the year, a STAT analysis shows.

Two emails, I received from the NCI this week contained studies that caught my eye.   Aged and BRCA mutated stromal cells drive epithelial c...

A type of stem cell appears to fuel the formation of cancerous lesions in the fallopian tubes and the lesions’ transition to ovarian cancer, a new study shows.

An ASCO Reading Room selection

Investigators have found that a concerningly low proportion of women diagnosed with ovarian cancer may be receiving the genetic testing that could help guide their treatment and potentially improve ou...

HPV-related lesions after hysterectomy for high-grade cervical intraepithelial neoplasia and early-stage cervical cancer: A focus on the potential role of va...

Relacorilant plus nab-paclitaxel demonstrated improved PFS and OS in platinum-resistant ovarian cancer.

In a study on ovarian cancer cells, researchers from Karolinska Institutet demonstrate how the tumor environment influences how cancer cells respond to drugs by using AI. The study has been published ...

Open notes are an important tool for improving patient safety.

Emily M. Hinchcliff, MD, MPH, discusses how the addition of immunotherapy to chemotherapy has influenced the endometrial cancer treatment paradigm.